Navigation Links
Boston Scientific's Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
Date:10/22/2007

stent design and a reduction in strut thickness may contribute to improved clinical outcomes for TAXUS Liberte in these difficult and challenging lesions."

"Results from the TAXUS ATLAS studies demonstrate the successful transfer of Boston Scientific's leading paclitaxel technology to our next-generation TAXUS Liberte Stent," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "Improved clinical outcomes and positive data on deliverability in complex lesions are a powerful demonstration of the continued leadership of Boston Scientific and our TAXUS Stent platform. TAXUS Liberte is the preferred drug-eluting stent in virtually every country where it is sold, and we look forward to bringing this technology to the U.S. in 2008."

The TAXUS ATLAS Small Vessel and Long Lesion studies are global, multi- center, historically controlled trials investigating de novo lesions in 411 patients at 24 sites. The Small Vessel study was designed to evaluate the safety and efficacy of the TAXUS Liberte 2.25 mm Stent for superiority compared to a case-matched historical bare-metal stent (BMS) control (Express Stent), and non-inferiority against a case-matched historical control of TAXUS Express Stent patients. The Long Lesion study was designed to demonstrate that the TAXUS Liberte Long (38 mm) Stent is non-inferior in safety and efficacy compared to a case-matched historical control of TAXUS Express Stent patients.

The Small Vessel study met its primary superiority endpoint compared to the BMS group (45.6% vs. 32.1% diameter stenosis, p<0.0001) and non- inferiority compared to the TAXUS Express group (38.4% vs. 32.1% diameter stenosis, p=0.0351). The TAXUS Liberte 2.25 mm Stent showed significant statistical reduction in target lesion revascularization (TLR) at nine months with a rate of 5.8% as compared to 13.7% in the TAXUS Express Stent (p=0.024), resulting in a 58% relative reduction. Overall target vessel revascularization (TVR) was 10.1% for th
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Boston Scientific Announces Schedule for EuroPcr 2007
2. Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons
3. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
4. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
5. To Stent or Not: Is That the Question?
6. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
9. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
10. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
11. Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial Results at EuroPCR 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... 15 West Pharmaceutical Services, Inc. (NYSE: ... Directors has approved payment of the first-quarter 2010 cash ... paid on February 3, 2010 to shareholders of record ... ,, West is a global manufacturer of components ... seals for vials, and closures and disposable components used ...
(Date:12/15/2009)... 15 SRI International, an independent nonprofit ... of U.S. patent 7,592,021 for a new bioadhesive ... drugs through the human body,s mucous membranes. This ... allows for a much longer release time compared ... Transmucosal delivery is an effective means to introduce ...
(Date:12/15/2009)... SINGAPORE, Dec. 15 ... that it has completed the previously announced ... manufacturer of disposable medical devices ranging from ... surgery. Through its medical segment, Flextronics provides ... device, medical equipment, and pharmaceutical customers. Terms ...
Breaking Medicine Technology:SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 2SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 3SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 4SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 5Flextronics Completes SloMedical Acquisition 2Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 1Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 2Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 3Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 4Macomb County Health Department Schedules Communitywide H1N1 Flu Vaccine Clinic Nov 24 61652 1Macomb County Health Department Schedules Communitywide H1N1 Flu Vaccine Clinic Nov 24 61652 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 1National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 3
... is Designed to Differentiate Squamous From, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Classifying ... of 90 ... Percent., Accurate Diagnosis is Important ... Potential Higher Rates of Severe or Fatal Hemorrhage in Patients With Squamous ...
... 2 DermaGen AB today announced a,cash injection from ... Development and Ostersjostiftelsen. The capital will be used for,the ... be used to initiate a clinical phase 2a study ... has already received approval, and,to further develop the company,s ...
Other Medicine Technology:Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 2Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 3Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 4Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 5Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 6Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 7DermaGen AB Receives Over 1 Million Euros From a New Share Issue 2DermaGen AB Receives Over 1 Million Euros From a New Share Issue 3
(Date:12/16/2009)... 16 For ages, people from around the ... properties. Its soothing waters have a reputation that dates ... involvement with miracles. Now, with the introduction of two ... can enjoy the legendary benefits of Dead Sea salt ... lines contain all-natural Dead Sea salt and essential oils ...
(Date:12/16/2009)... More Americans have myopia now than in the ,70s, ... Myopia (nearsightedness) is more common in the United States ... National Eye Institute study shows. , Researchers compared National ... and white participants from 1971 to 1972 and from ... The participants were 12 to 54 years old. , ...
(Date:12/16/2009)... trial bottle sample with purchase of 90-count bottle. , ... ... announces a special free offer for a “Free 21-Count ... Formula , with the purchase of a 90-count bottle. Distributed ... in FDA approved facilities and blends the 6 most important medicinal ...
(Date:12/16/2009)... Request A Test, Ltd. is proud to announce being presented with ... Weatherhead 100 showcases the fastest growing companies in Northeast Ohio and ... to succeed. , ... (PRWEB) December ... being presented with the Weatherhead 100 Upstart Award on December 3, ...
(Date:12/16/2009)... perfect gift to give that special woman who has everything? ... Mary Schook introduces exceptional beauty products online while educating the public ... ... (PRWEB) December 16, 2009 -- The holidays are rapidly approaching ... woman who has everything? Why stem cells, of course!, , , ...
Breaking Medicine News(10 mins):Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 2Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 2Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 4Health News:Request A Test Receives Weatherhead 100 Upstart Award 2Health News:New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything 2
... CUR, QUEBEC CITY, June 3 /PRNewswire-FirstCall/ - Two ... the detection of prostate cancer,and GCC for the staging ... part of the growing trend to molecular diagnostics., ... the 34th,Annual International Clinical Ligand Assay Society Meeting, held ...
... Trainers For Peak ... Performance, LOS ANGELES, June 2 ... Cher, now the,Pussycat Dolls are working out with Bally. On the verge of ... for,their hot new single "When I Grow Up," the Pussycat Dolls are getting ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), the ... today that it has acquired,Physicians Home Health Care ... $12 million in cash. The transaction will be ... established by a group of physicians in 1984, ...
... of autoantibody-secreting cells, have emerged as promising new ... (RA). In particular, B cell depletion with ... RA patients resistant to standard disease-modifying antirheumatic drugs ... In large trials, about half of these ...
... 2 The International Rett Syndrome,Foundation announced today ... Chief Scientific Officer, beginning July 1. Dr. Horton ... of Rett,Clinics, a series of clinics throughout the ... addition, Dr. Horton will,assist the IRSF Board of ...
... There is still time to enter,the American Academy ... to boys and girls in two groups, grades 3-5 ... will be invited to attend,the 2008 AAP National Conference ... winners will receive $500 and up to $1,000 for ...
Other Medicine News:Health News:DiagnoCure's molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings 2Health News:DiagnoCure's molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings 3Health News:Pussycat Dolls Shape Up With Bally Total Fitness 2Health News:Gentiva(R) Health Services Acquires Leading Colorado Home Health Provider 2Health News:Gentiva(R) Health Services Acquires Leading Colorado Home Health Provider 3Health News:Study of anti-CD20 therapy effective B cell depletion 2Health News:The International Rett Syndrome Foundation Names Antony Horton Ph.D. Chief Scientific Officer 2
MP-250N and 300N is a new style power supply. It is a versatile microprocessor power supply for horizontal or vertical gel electrophoresis. The unit is programmable and offers constant voltage and co...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
... ZOOM® Dual Power is a microprocessor-controlled ... both high voltage/low current and high ... voltage/low current section is ideal for ... DNA sequencing applications. The low voltage/high ...
... Power Supply is designed specifically ... extensive programming capabilities, including eight ... for you to set to ... intuitive PowerEase® interface is faster ...
Medicine Products: